Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.68 |
| ▸ | KDR | P35968 | 16/20 | 0.68 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.54 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.54 |
| ▸ | STK10 | O94804 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | YES1 | P07947 | 1/20 | 0.54 |
| ▸ | LYN | P07948 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | HCK | P08631 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | FGR | P09769 | 1/20 | 0.54 |
| ▸ | KIT | P10721 | 1/20 | 0.54 |
| ▸ | BCR | P11274 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3675514 | 0.94 | SRC (0.70) | SRCKDRBMPR1BGAKEPHB6 | |
| SCHEMBL3675255 | 0.93 | SRC (0.74) | SRCKDRBMPR1BGAKEPHB6 | |
| SCHEMBL3677564 | 0.92 | SRC (0.73) | SRCKDRBMPR1BGAKEPHB6 | |
| SCHEMBL3675427 | 0.92 | SRC (0.81) | SRCKDRBMPR1BGAKEPHB6 | |
| Azd-0424 SCHEMBL29382167 | 0.91 | SRC (0.73) | SRCKDRBMPR1BGAKEPHB6 | |
| Azd-0424 SCHEMBL3202072 | 0.91 | SRC (0.73) | SRCKDRBMPR1BGAKEPHB6 | |
| SCHEMBL3202589 | 0.91 | SRC (0.68) | SRCKDRBMPR1BGAKEPHB6 | |
| SCHEMBL3676658 | 0.90 | SRC (0.66) | SRCKDRBMPR1BGAKEPHB6 | |
| SCHEMBL3210348 | 0.88 | SRC (0.61) | SRCKDRBMPR1BGAKEPHB6 | |
| SCHEMBL3672594 | 0.88 | SRC (0.75) | SRCKDRBMPR1BGAKEPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462623-B2 | Quinazoline derivatives as Src tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2008-12-09 | — | — | US | claimed |
| EP-1562955-B1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | claimed |
| US-20060122199-A1 | Quinazoline derivatives as src tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | claimed |
| EP-1562955-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | Astrazeneca AB (SE) | 2005-08-17 | — | — | EP | claimed |
| WO-2004041829-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | claimed |
| EP-1562612-B1 | COMBINATION PRODUCT OF INHIBITOR OF THE SRC FAMILY OF NON-RECEPTOR TYROSINE KINASES AND GEMCITABINE FOR USE IN THE TREATMENT OR PROPHLAXIX OF PANCREATIC CANCER | ASTRAZENECA AB (SE) | 2010-01-27 | — | — | EP | disclosed |
| WO-2009068906-A2 | COMBINATIONS COMPRISING ZD4054 AND A SRC FAMILY KINASE INHIBITOR 172 | ASTRAZENECA AB (SE) | 2009-06-04 | — | — | WO | disclosed |
| US-7462623-B2 | Quinazoline derivatives as Src tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2008-12-09 | — | — | US | disclosed |
| EP-1562955-B1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | US | disclosed |
| US-20060122199-A1 | Quinazoline derivatives as src tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| EP-1562612-A1 | COMBINATION PRODUCT OF INHIBITOR OF THE SRC FAMILY OF NON-RECEPTOR TYROSINE KINASES AND GEMCITABINE | Astrazeneca AB (SE) | 2005-08-17 | — | — | EP | disclosed |
| EP-1562955-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | Astrazeneca AB (SE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004043472-A1 | COMBINATION PRODUCT OF INHIBITOR OF THE SRC FAMILY OF NON-RECEPTOR TYROSINE KINASES AND GEMCITABINE | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004041829-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | SRC, PTPN4, PTPN1 | SRC 1/4885KDR 825/4885BMPR1B 3903/4885 |
| US-20060122199-A1 | Quinazoline derivatives as src tyrosine kinase inhibitors | SRC, ABL1, ERBB2 | SRC 1/4885KDR 118/4885BMPR1B 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.